Shares of Biomea Fusion Inc. (NASDAQ:BMEA) rocketed up 89% to close at $29.30 March 28 after the company reported early cohort data from its Covalent-111 phase I/II trial, showing treatment with the lowest dose of menin inhibitor BMF-219 reduced median A1c levels in patients with type 2 diabetes by 1% at only four weeks.